Intervention Effect of Oropharyngeal Administration of Colostrum in Preterm Infants: A Meta-Analysis
Mengyue Huo1, Chunli Liu1, Hua Mei1
1Department of Neonatology, Affiliated Hospital, Inner Mongolia Medical University, Hohhot, China.
Insights
Oropharyngeal administration of colostrum (OAC) significantly reduces necrotizing enterocolitis, late-onset sepsis, and ventilator-associated pneumonia in preterm infants. OAC also improves weight gain and shortens hospital stays, supporting its use in routine care.
Area of Science:
- Neonatal Medicine and Perinatology
- Clinical Nutrition and Gastroenterology
Background:
- Preterm infants are highly susceptible to infections and feeding complications.
- Oropharyngeal administration of colostrum (OAC) is being explored as a supportive therapy for preterm neonates.
Approach:
- A systematic review and meta-analysis of 11 randomized controlled trials (RCTs) involving 1,173 preterm infants (gestational age ≤ 32 weeks or birth weight ≤ 1500 g).
- Searched major databases (Embase, MEDLINE, CENTRAL, CINAHL) up to February 2022.
- Compared OAC with placebo or no intervention.
Key Points:
- OAC significantly reduced the incidence of necrotizing enterocolitis (NEC; RR=0.51), late-onset sepsis (LOS; RR=0.75), and ventilator-associated pneumonia (VAP; RR=0.48).
- OAC shortened the time to full enteral feeds (MD=-3.40 days) and duration of hospital stay (MD=-10.00 days).
- OAC significantly increased the rate of weight gain (MD=2.63 kg/d) without increasing risks for BPD, IVH, PVL, ROP, or PDA.
Conclusions:
- Oropharyngeal colostrum administration is an effective intervention for improving outcomes in preterm infants.
- OAC reduces the incidence of serious infections and feeding-related complications.
- OAC supports faster growth and shorter hospitalizations, suggesting its integration into standard neonatal care.
Objective:
To evaluate the efficacy and safety of oropharyngeal administration of colostrum (OAC) in preterm infants.
Methods:
We searched Embase, MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the website of the clinical trials, search time was from the establishment of the databases or websites up to 1 February 2022. Preterm infants with gestational age (GA) ≤ 32 weeks or birth weight (BW) ≤ 1500 g were taken as the participants, collect randomized controlled trials (RCTs) of comparing OAC and placebo or no intervention in preterm infants. Two researchers independently screened the literature, extracted the data, and evaluated the quality of the literature, and we adopted Review Manager 5.3 software for meta-analysis.
Results:
In total, 11 RCTs (n = 1,173) were included in the review. A meta-analysis showed significant difference in the incidence of necrotizing enterocolitis [NEC; p = 0.009, relative ratio (RR) = 0.51, 95% confidence interval (CI) = 0.31-0.84], late-onset sepsis (LOS; p = 0.02, RR = 0.75, 95% CI = 0.59-0.95), ventilator-associated pneumonia (VAP; p = 0.03, RR = 0.48, 95% CI = 0.24-0.95), the time to reach full enteral feeds (p < 0.00001, mean difference (MD) = -3.40, 95% CI = -3.87 to -2.92), duration of hospital stay (p < 0.00001, MD = -10.00, 95% CI = -11.36 to -8.64), and the rate of weight gain (kg.d; p < 0.00001, MD = 2.63, 95% CI = 2.10-3.16) between the colostrum group and control group. Meanwhile, researchers found no significant difference between the colostrum group and control group in the incidence of bronchopulmonary dysplasia (BPD; p = 0.17, RR = 0.83, 95% CI = 0.64-1.08), intraventricular hemorrhage (IVH; grade ≥3; p = 0.05, RR = 0.44, 95% CI = 0.19-1.01), periventricular leukomalacia (PVL; p = 0.67, RR = 0.70, 95% CI = 0.14-3.49), retinopathy of prematurity (ROP; p = 0.29, RR = 1.25, 95% CI = 0.82-1.89), and patent ductus arteriosus (PDA; p = 0.17, RR = 1.22, 95% CI = 0.92-1.62).
Conclusion:
Oropharyngeal administration of colostrum can reduce the incidence of NEC, LOS, and VAP in preterm infants, shortening the time to reach full enteral feeds, and duration of hospital stay, and increasing the rate of weight gain (kg.d). Therefore, OAC can be used as part of routine care for preterm infants.
Related Concept Videos
Drug Dosing: Infants and Children
Development of the Oral Microbiota


